Rhophylac ZLB Bioplasma AG, Switzerland - Treatment for Prevention of Rho(D) Sensitization

Rhophylac is a highly purified, plasma-derived product comprised of Rho(D) Immune Globulin (Human) for IV or IM administration. Rhophylac is primarily indicated for the prevention of hemolytic disease of the fetus and newborn (HDN), and also indicated to prevent Rho(D) sensitization after transfusion of Rh-positive blood type to Rh-negative patient.

Posted: February 2004

Related Articles:

Rhophylac (Rh0(D) immune globulin intravenous (human)) FDA Approval History

View comments

Hide
(web5)